SCHEMBL9901869

SCHEMBL9901869

NC(=O)c1c[c]c(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.41
PARP10 Q53GL7 9/20 0.40
PARP4 Q9UKK3 2/20 0.40
PARP15 Q460N3 2/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
PARP14 Q460N5 1/20 0.40
PARP16 Q8N5Y8 1/20 0.40
PARP11 Q9NR21 1/20 0.40
PLA2G10 O15496 1/20 0.39
PLA2G2A P14555 1/20 0.39
TSHR P16473 2/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185207 0.80 TSHR (0.48) ALDH1A1TSHRPOLBMAPTHSD17B10
SCHEMBL1206454 0.78 KMT2A (0.45) ALDH1A1KMT2AMAPTTDP1L3MBTL1
SCHEMBL1303104 0.77 PARP10 (0.43) PARP1PARP10PARP4PARP15ALDH1A1
SCHEMBL7304754 0.76 PARP10 (0.41) PARP1PARP10PARP4PARP15ALDH1A1
SCHEMBL9900228 0.75 ALDH1A1 (0.47) ALDH1A1KMT2APOLBCYP3A4MAPT
SCHEMBL96927 0.74 PARP1 (0.41) PARP1PARP10PARP4PARP15ALDH1A1
SCHEMBL11145825 0.74 PARP10 (0.42) PARP1PARP10PARP4PARP15ALDH1A1
SCHEMBL12615099 0.74 HDAC8 (0.48) TSHRCA2SMN1; SMN2
SCHEMBL27995848 0.74 CA1 (0.48) ALDH1A1KMT2ATSHRPOLBMAPT
SCHEMBL5140546 0.74 MAOB (0.37) PARP1PARP10PARP4PARP15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542526-B Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-01-09 CN claimed
EP-3697789-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2020-08-26 EP claimed
CN-111542526-A Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor 因赛特公司 2020-08-14 CN claimed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 WO claimed
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 US claimed
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 EP claimed
CN-108419435-A Compound and epigenetics for treating cancer 新加坡科技研究局 2018-08-17 CN claimed
WO-2017061957-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-04-13 WO claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP claimed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO claimed
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2024-07-11 US disclosed
CN-118063470-A Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-05-24 CN disclosed
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2024-03-12 US disclosed
CN-111542526-B Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-01-09 CN disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS SMYD3, SMYD2, EHMT1 PARP1 615/4885PARP10 348/4885PARP4 606/4885
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD PARP1 700/4885PARP10 2087/4885PARP4 2428/4885
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 PARP1 186/4885PARP10 228/4885PARP4 790/4885
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors PIK3R5, PIK3CG, PIK3CD PARP1 554/4885PARP10 2289/4885PARP4 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.